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Background: The objective of this study was to investigate the characteristics, treatment and prognosis
of early versus late recurrence of intrahepatic cholangiocarcinoma (ICC) after hepatic resection.
Methods: Patients who underwent resection with curative intent for ICC were identified from a
multi-institutional database. Data on clinicopathological characteristics, initial operative details, timing
and sites of recurrence, recurrence management and long-term outcomes were analysed.
Results: A total of 933 patients were included. With a median follow-up of 22 months, 685 patients
(73⋅4 per cent) experienced recurrence of ICC; 406 of these (59⋅3 per cent) developed only intrahepatic
disease recurrence. The optimal cutoff value to differentiate early (540 patients, 78⋅8 per cent) versus late
(145, 21⋅2 per cent) recurrence was defined as 24 months. Patients with early recurrence had extrahepatic
disease more often (44⋅1 per cent versus 28⋅3 per cent in those with late recurrence; P <0⋅001), whereas
late recurrence was more often only intrahepatic (71⋅7 per cent versus 55⋅9 per cent for early recurrence;
P < 0⋅001). From time of recurrence, overall survival was worse among patients who had early versus
late recurrence (median 10 versus 18 months respectively; P =0⋅029). In multivariable analysis, tumour
characteristics including tumour size, number of lesions and satellite lesions were associated with an
increased risk of early intrahepatic recurrence. In contrast, only the presence of liver cirrhosis was
independently associated with an increased likelihood of late intrahepatic recurrence (hazard ratio 1⋅99,
95 per cent c.i. 1⋅11 to 3⋅56; P =0⋅019).
Conclusion: Early and late recurrence after curative resection for ICC are associated with different
risk factors and prognosis. Data on the timing of recurrence may inform decisions about the degree
of postoperative surveillance, as well as help counsel patients with regard to their risk of recurrence.
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Introduction
Intrahepatic cholangiocarcinoma (ICC) is the second most
common primary liver tumour after hepatocellular carci-
noma (HCC), accounting for 10–15 per cent of all pri-
mary liver cancers1,2. Although relatively rare, ICC is a
fatal malignancy, which often has a more aggressive tumour
biology than HCC3. In fact, among patients who present
with advanced and/or metastatic disease, the overall 5-year
survival rate is dismal at just 5–10 per cent4. For the 20–40
per cent of patients with ICC who present with opera-
ble disease, surgical resection remains the only potentially
curative treatment option for ICC5,6. Even after resection
with curative intent, the 5-year survival rate is still only
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20–35 per cent4,7. The main reason for the poor long-term
oncological outcomes relates to the incidence of recur-
rence, which can be as high as 54–71 per cent7–9.
Several studies have investigated the risk factors, as well
as the management, associated with recurrent ICC after
resection with curative intent7–9. The risk of recurrence
has generally been associated with biological factors indica-
tive of tumour aggressiveness, as well as technical factors
such as a positive surgical margin7–9. In addition, similar
to HCC, the majority of ICC recurrences after hepatic
resection occur in the liver remnant7,8,10. In patients with
HCC, the aetiology of recurrences has been attributed to
either intrahepatic metastasis from the initial tumour or
a de novo tumour10,11. In clinical practice, the differentia-
tion between a recurrence and development of a de novo
tumour can be challenging and relies largely on genetic or
molecular studies of the clonal origin of the tumours12,13.
Early recurrence after resection of HCC has been asso-
ciated with certain tumour pathological characteristics,
whereas late recurrence has been related to underlying
liver disease14–17. In turn, early recurrence is more likely
to be ‘recurrent’ disease, whereas late recurrence is more
often a representation of a metachronous second primary
lesion14–17.
Although early versus late recurrence has been examined
extensively among patients with HCC, the topic has been
poorly studied in those with ICC. Data on risk factors,
patterns of recurrence, and outcomes in patients with early
versus late recurrence may have important implications for
postoperative surveillance and adjuvant therapy, as well as
management of the recurrence10,17. The objective of the
present study was to define the risk factors, treatment and
prognosis of patients with early versus late recurrence of
ICC after surgery with curative intent. In addition, the
implications of early versus late recurrence on long-term
outcomes among patients with ICC were characterized.
Methods
Patients undergoing hepatic resection with curative intent
for ICC from 1990 to 2016 at one of 14 major hepatobiliary
centres in North America, Europe, Australia and Asia were
included in the study. Patients with extrahepatic metastasis
at the time of surgery and those undergoing palliative
resection, ablation only or intra-arterial therapy only were
excluded. Additionally, patients who were lost to follow-up,
those who did not have detailed information regarding
site of recurrence, and patients who died within 30 days of
surgery were excluded. All patients were diagnosed with
histologically confirmed ICC. The Institutional Review
Boards of each participating institution approved the study.
Data collection and follow-up
Demographic and clinicopathological variables were col-
lected for each patient. Liver cirrhosis was diagnosed based
on histological examination of pathological specimens.
Tumour size, number and morphology, vascular, perineu-
ral, biliary and adjacent organ invasion, lymph node metas-
tasis and histological grade were also documented based
on final pathology reports. Data on tumour stage were
collected according to the AJCC seventh edition staging
system18. Patients were followed regularly after surgery
with assessment of serum carbohydrate antigen 19-9, car-
cinoembryonic antigen levels, and abdominal CT or MRI.
Recurrence was defined as suspicious imaging findings
or biopsy-proven tumour. Sites of recurrence were catego-
rized as intrahepatic, extrahepatic, or both intrahepatic and
extrahepatic. Overall survival (OS) and recurrence-free sur-
vival were calculated from the date of surgery. OS after the
first recurrence was calculated from the date of recurrence
and was used to compare the outcome of patients with early
and late recurrence.
Treatment of recurrence
When tumour recurrence was diagnosed, the therapeutic
strategy was evaluated based on tumour location, num-
ber of tumours, general patient condition and liver func-
tion. Treatment with curative intent, including surgical
re-resection, ablation or both, was considered for patients
with only intrahepatic recurrence. Other treatments were
individualized for patients with advanced recurrent dis-
ease, and included intra-arterial therapy, chemotherapy
and radiotherapy, depending on disease extent and the
patient’s performance status.
Statistical analysis
Continuous variables are expressed as median (i.q.r.) and
compared with Student’s t test or the Mann–Whitney U
test. Categorical variables are expressed as numbers and
percentages, and compared with the χ2 test or Fisher’s exact
test. Kaplan–Meier curves with log rank tests were used
to compare survival. Univariable and multivariable logistic
regression models were used to determine factors associ-
ated with ‘any site’ and intrahepatic-only recurrence. Haz-
ard ratios (HRs) and 95 per cent confidence intervals were
estimated by means of multivariable analysis. Variables with
a P value of less than 0⋅100 in univariable analysis were
entered into the multivariable model. A two-tailed P value
greater than 0⋅050 was considered statistically significant.
Statistical analysis was performed using SPSS® 22.0 (IBM,
Armonk, New York, USA).
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Intrahepatic and extrahepatic recurrence
Fig. 1 a Cumulative recurrence among patients with intrahepatic cholangiocarcinoma (ICC) who underwent surgery with curative
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Fig. 2 Determination of the optimal cutoff value for early and late
recurrence of intrahepatic cholangiocarcinoma (ICC).
Recurrence was divided into two periods according to the slope
of the curves identified with linear regression. The function of
the two lines was y= 32⋅85− 1⋅225x and y= 7⋅3143− 0⋅1181x
respectively. The intercept value of the two lines was 23 months;
24 months was thus defined as the optimal cutoff value to
differentiate early and late recurrence of ICC
Results
A total of 1142 patients were identified from the 14 insti-
tutions. Thirty-two patients were excluded because of
extrahepatic metastasis at the time of surgery, palliative
resection, ablation alone or intra-arterial therapy alone.
A further 89 patients were lost to follow-up, did not
have detailed information regarding site of recurrence (30
patients) or died within 30 days of surgery (58; in-hospital
death rate 5⋅1 per cent) and were therefore excluded. A total
933 patients undergoing curative resection for ICC were
included in the analysed cohort.
With a median follow-up of 22 months, 440 patients
(47⋅2 per cent) had died. Cumulative 1-, 3- and 5-year OS
rates were 82, 53 and 41 per cent respectively. Of these 440
patients, 397 (90⋅2 per cent) died from tumour recurrence
and 43 (9⋅8 per cent) from other causes. Some 292 patients
(31⋅3 per cent) were alive at last follow-up with tumour
recurrence. The cumulative recurrence rate at 1, 3 and
5 years was 44, 65 and 70 per cent respectively (Fig. 1a). In
total, 685 patients (73⋅4 per cent) developed recurrence, of
whom 406 (59⋅3 per cent) had intrahepatic disease only, 94
(13⋅7 per cent) had extrahepatic disease only, and 185 (27⋅0
per cent) had both intrahepatic and extrahepatic disease.
The lungs, distal lymph nodes and peritoneum were the
most common sites of extrahepatic recurrence (23⋅7, 24⋅7
and 16⋅1 per cent respectively).
Patients with no postoperative recurrence had a bet-
ter survival than those who developed ICC recurrence
(P < 0⋅001) (Fig. 1b). Notably, patients who had recurrent
intrahepatic disease alone had a longer median OS than
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Table 1 Clinical and pathological characteristics of patients with early versus late recurrence following initial surgery for intrahepatic
cholangiocarcinoma
Early recurrence (n=540) Late recurrence (n=145) P†
Age (years)* 58 (49–68) 61 (54–67) 0⋅139‡
Men 313 (58⋅0) 74 (51⋅0) 0⋅129
BMI (kg/m2)* 25⋅3 (22⋅3–28⋅0) 25⋅2 (22⋅2–28⋅0) 0⋅889‡
Liver cirrhosis 62 (11⋅5) 31 (21⋅4) 0⋅002
Carbohydrate antigen 19-9 (units/ml)* 53⋅8 (16⋅0–272⋅3) 33⋅0 (11⋅2–90⋅0) 0⋅878‡
Carcinoembryonic antigen (ng/ml)* 2⋅4 (1⋅3–4⋅3) 2⋅2 (1⋅5–3⋅6) 0⋅911‡
Tumour size (cm)* 6⋅5 (4⋅8–9⋅0) 6⋅0 (3⋅8–8⋅0) 0⋅019‡
Multiple lesions (≥ 2) 120 (22⋅2) 16 (11⋅0) 0⋅002
Bilobar tumour 102 (18⋅9) 21 (14⋅5) 0⋅272
Vascular invasion
Macro 65 (12⋅0) 13 (9⋅0) 0⋅377
Micro 155 (28⋅7) 29 (20⋅0) 0⋅044
Perineural invasion 87 (16⋅1) 20 (13⋅8) 0⋅604
Direct invasion of adjacent organs 47 (8⋅7) 8 (5⋅5) 0⋅300
Biliary invasion 76 (14⋅1) 17 (11⋅7) 0⋅571
Satellite lesions 152 (28⋅1) 20 (13⋅8) < 0⋅001
AJCC tumour category 0⋅056
T1–2 413 (76⋅5) 114 (78⋅6)
T3–4 101 (18⋅7) 16 (11⋅0)
Missing 26 (4⋅8) 15 (10⋅3)
AJCC node category 0⋅009
N0 284 (52⋅6) 77 (53⋅1)
N1–2 117 (21⋅7) 17 (11⋅7)
Nx 139 (25⋅7) 51 (35⋅2)
Histological grade 0⋅263
Well to moderately differentiated 422 (78⋅1) 117 (80⋅7)
Poorly to undifferentiated 100 (18⋅5) 20 (13⋅8)
Missing 18 (3⋅3) 8 (5⋅5)
Morphological type 0⋅147
Mass-forming 428 (78⋅2) 106 (73⋅1)
Papillary 13 (2⋅4) 8 (5⋅5)
Periductal infiltrating 24 (4⋅4) 6 (4⋅1)
Mass-forming + periductal infiltrating 52 (9⋅6) 9 (6⋅2)
Missing 23 (4⋅3) 16 (11⋅0)
Resection procedure 0⋅557
Minor 220 (40⋅7) 63 (43⋅4)
Major 320 (59⋅3) 82 (56⋅6)
R0 resection 472 (87⋅4) 130 (89⋅7) 0⋅566
Margin distance (mm) 0⋅013
< 1 68 (12⋅6) 15 (10⋅3)
1–4 197 (36⋅5) 41 (28⋅3)
5–9 115 (21⋅3) 27 (18⋅6)
≥ 10 126 (23⋅3) 53 (36⋅6)
Missing 34 (6⋅3) 9 (6⋅2)
Major vascular resection 61 (11⋅3) 15 (10⋅3) 0⋅882
Bile duct resection 99 (18⋅3) 22 (15⋅2) 0⋅462
Lymphadenectomy 269 (49⋅8) 69 (47⋅6) 0⋅634
Intraoperative blood loss (ml)* 450 (200–800) 400 (200–600) 0⋅405‡
Duration of surgery (min)* 200 (120–310) 205 (120–355) 0⋅773‡
Adjuvant chemo/radiotherapy 197 (36⋅5) 48 (33⋅1) 0⋅294
Postoperative complications 189 (35⋅0) 53 (36⋅6) 0⋅729
Values in parentheses are percentages unless indicated otherwise; *values are median (i.q.r.). †χ2 or Fisher’s exact test, except ‡Student’s t test or
Mann–Whitney U test.
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Fig. 3 Sites of recurrence in patients who had early or late
recurrence following surgery with curative intent for intrahepatic
cholangiocarcinoma. *P = 0⋅003 (χ2 test)
those with only extrahepatic recurrent disease (40 versus
23 months respectively; P = 0⋅003), as well as patients who
developed both intrahepatic and extrahepatic disease (40
versus 22 months; P < 0⋅001) (Fig. 1b).
Optimal cutoff value for early and late recurrence
To determine the optimal cutoff value to distinguish
between early and late recurrence, recurrence was
evaluated at 6-month time points. Twenty-four months
was defined as the optimal cutoff value, as explained in
Fig. 2.
Clinicopathological data and outcomes after recurrence
were analysed and compared between the early and late
recurrence groups.
Outcomes following early and late recurrence
at any site
The time duration from the date of initial hepatic surgery
to tumour recurrence was documented among the 685
patients with recurrence. A total of 540 patients (78⋅8 per
cent) who developed recurrence within 24 months were
defined as having early recurrence, and 145 (21⋅2 per
cent) who had recurrence 24 months or more after first
hepatic surgery were defined as having late recurrence.
Although many of the clinicopathological and operative
data from the time of initial surgery were comparable
between the two groups, liver cirrhosis was more common
among patients who experienced a late versus an early
recurrence (P = 0⋅002) (Table 1). Hepatitis B virus (HBV)
and hepatitis C virus (HCV) infection were the two most
common causes of liver cirrhosis: 73 (78 per cent) of the 93
patients with liver cirrhosis who developed recurrence had
hepatitis. Early recurrence occurred more commonly in
patients with tumours that had more aggressive biological
Table 2 Risk factors for early and late recurrence of intrahepatic cholangiocarcinoma at any site
Early recurrence (n=540) Late recurrence (n=145)
Multivariable analysis Multivariable analysis
Univariable P Hazard ratio P Univariable P Hazard ratio P
Sex (M : F) 0⋅256 0⋅336
Liver cirrhosis 0⋅008 0⋅81 (0⋅52, 1⋅19) 0⋅252 0⋅029 1⋅89 (1⋅09, 3⋅26) 0⋅023
Tumour size (cm) < 0⋅001 0⋅244
≤ 5 1⋅00 (reference)
5–10 1⋅67 (1⋅02, 2⋅90) 0⋅038
≥ 10 2⋅12 (1⋅49, 3⋅04) < 0⋅001
Multiple tumours < 0⋅001 1⋅18 (0⋅72, 1⋅93) 0⋅507 1⋅000
Bilobar disease 0⋅304 0⋅459
Macrovascular invasion 0⋅084 1⋅19 (0⋅74, 2⋅21) 0⋅447 0⋅756
Microvascular invasion 0⋅018 1⋅34 (0⋅86, 2⋅14) 0⋅189 0⋅702
Perineural invasion 0⋅084 1⋅08 (0⋅67, 1⋅74) 0⋅816 0⋅419
Biliary invasion 0⋅468 0⋅866
Direct invasion of adjacent organs 0⋅002 1⋅71 (0⋅73, 4⋅16) 0⋅252 0⋅156
Satellite lesions < 0⋅001 2⋅0 (1⋅32, 3⋅15) 0⋅002 0⋅640
Poorly differentiation to undifferentiated 0⋅023 1⋅13 (0⋅70, 1⋅68) 0⋅678 0⋅637
AJCC tumour category 0⋅008 0⋅871
T1–2 1⋅00 (reference)
T3–4 1⋅0 (0⋅64, 1⋅66) 0⋅944
AJCC node category < 0⋅001 0⋅379
N0 1⋅00 (reference)
N1 1⋅3 (1⋅01, 1⋅63) 0⋅028
Adjuvant chemo/radiotherapy < 0⋅001 0⋅67 (0⋅46, 0⋅97) 0⋅029 0⋅022 0⋅7 (0⋅4, 1⋅2) 0⋅218
Values in parentheses are 95 per cent confidence intervals.
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Fig. 4 Overall survival a from date of diagnosis of recurrence stratified by early versus late recurrence and b following initial surgery for
intrahepatic cholangiocarcinoma (ICC) in patients with no recurrence, patients with recurrence of ICC treated with curative intent and
those with recurrence treated non-curatively. a P = 0⋅029, b P < 0⋅001 (log rank test)
features, including larger size (P = 0⋅019), multiple lesions
(P = 0⋅002), and the presence of microvascular invasion
(P = 0⋅044) or satellite lesions (P < 0⋅001). Although the
type and extent of surgery were no different between
the two groups, more patients with early recurrence had
a narrow surgical margin than those with late recur-
rence (margin less than 1 cm: 70⋅4 versus 57⋅2 per cent
respectively; P = 0⋅003).
Intrahepatic-only recurrence was more common in
patients who had a late recurrence (104 (71⋅7 per cent)
versus 302 (55⋅9 per cent) in those with early recurrence;
P < 0⋅001), whereas extrahepatic recurrence was more
common in patients with an early recurrence (238 (44⋅1
per cent) versus 41 (28⋅3 per cent) with a late recurrence;
P < 0⋅001) (Fig. 3).
Factors associated with early recurrence after initial
hepatectomy were investigated among all 933 patients in
the analysed cohort. Factors related to late recurrence
were investigated among the 393 patients who were free of
recurrence in the first 24 months after the index operation.
Tumour characteristics, including increasing tumour size,
satellite lesions and lymph node metastasis, were asso-
ciated with an increased likelihood of early recurrence,
whereas adjuvant chemo/radiotherapy was associated
with a decreased risk of early recurrence (Table 2). In
contrast, only the presence of liver cirrhosis was indepen-
dently associated with an increased risk of late recurrence.
Following recurrence, median OS was lower among
patients who developed early recurrence than in those
with late recurrence (10 versus 18 months respectively;
P = 0⋅029) (Fig. 4a).
Risk factors and outcome after early and late
intrahepatic-only recurrence
For intrahepatic-only recurrence, tumour size, number of
tumours and satellite lesions were independent risk factors
for early intrahepatic recurrence (Table 3). Liver cirrhosis
was the only independent risk factor for late recurrence.
Of the 406 patients who had an intrahepatic recurrence,
327 (80⋅5 per cent) had treatment for the recurrent disease
(274 with early and 53 with late intrahepatic recurrence).
One-quarter of patients (70 of 274, 25⋅5 per cent) with
early intrahepatic recurrence had treatment with curative
intent (surgical resection, 61; ablation, 9), whereas 62 per
cent (33 of 53) of those with late intrahepatic recurrence
underwent potentially curative therapy (surgical resection,
20; ablation, 13) (P < 0⋅001).
Median OS after resection and ablation were com-
parable (124 months versus median not reached for
ablation; P = 0⋅543). Palliative treatments including repeat
intra-arterial therapy and systemic chemotherapy were
undertaken in 74⋅5 per cent (204 of 274) of patients with
early intrahepatic recurrence and 38 per cent (20 of 53) of
those with late intrahepatic recurrence.
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Table 3 Risk factors for early and late intrahepatic-only recurrence of intrahepatic cholangiocarcinoma
Early recurrence (n=302) Late recurrence (n=104)
Multivariable analysis Univariable analysis
Univariable P Hazard ratio P Hazard ratio P
Sex (M : F) 0⋅529 0⋅171
Liver cirrhosis 0⋅063 0⋅84 (0⋅53, 1⋅27) 0⋅337 1⋅99 (1⋅11, 3⋅56) 0⋅019
Tumour size (cm) < 0⋅001 0⋅436
≤ 5 1⋅00 (reference)
5–10 1⋅58 (0⋅92, 2⋅72) 0⋅105
≥ 10 1⋅87 (1⋅34, 2⋅81) 0⋅001
Multiple tumours < 0⋅001 1⋅62 (1⋅03, 2⋅72) 0⋅052 0⋅644
Bilobar disease 0⋅726 0⋅429
Macrovascular invasion 0⋅985 0⋅834
Microvascular invasion 0⋅064 1⋅09 (0⋅74, 1⋅73) 0⋅632 0⋅223
Perineural invasion 0⋅095 1⋅16 (0⋅69, 1⋅87) 0⋅577 0⋅767
Biliary invasion 0⋅895 0⋅320
Direct invasion of adjacent organs 0⋅037 1⋅58 (0⋅56, 4⋅24) 0⋅367 0⋅457
Satellite lesions < 0⋅001 1⋅85 (1⋅22, 3⋅13) 0⋅008 1⋅000
Poorly differentiated to undifferentiated 0⋅166 0⋅725
R1 margin 0⋅069 1⋅33 (0⋅74, 2⋅30) 0⋅476 0⋅633
AJCC tumour category 0⋅116 0⋅352
T1–2
T3–4
AJCC node category 0⋅001 0⋅469 1⋅000
N0 1⋅00 (reference)
N1 1⋅14 (0⋅93, 1⋅32)
Adjuvant chemo/radiotherapy 0⋅008 0⋅66 (0⋅52, 1⋅11) 0⋅142 0⋅311
Values in parentheses are 95 per cent confidence intervals.
From the time of ICC recurrence, patients with early
intrahepatic disease tended to have a worse OS than those
with late intrahepatic disease (median 13 versus 24 months
respectively; P = 0⋅190). However, subsequent OS follow-
ing curative treatment of the recurrence was no different
in early and late recurrence groups (median OS 51 versus
55 months respectively; P = 0⋅654). Following treatment
with curative intent of the recurrence (103 of 327 patients:
70 of 274 with early and 33 of 53 with late intrahepatic
recurrence), 1-, 3- and 5-year OS rates were 94⋅8, 79⋅5 and
63⋅7 per cent respectively, comparable to rates in the 248
patients who had no recurrence (91⋅1, 83⋅7 and 77⋅1 per
cent respectively) (P = 0⋅270) (Fig. 4b). Of note, patients
with intrahepatic recurrence who did not undergo treat-
ment with curative intent (224 of 327: 204 with early and
20 with late intrahepatic recurrence) had worse long-term
outcomes (1-, 3- and 5-year OS rates of 73⋅1, 31⋅5 and 20⋅1
per cent respectively; P < 0⋅001).
Discussion
Even when surgical resection with curative intent is per-
formed, the prognosis of patients with ICC is poor owing
to a high incidence of recurrence, which may occur early or
late. The optimal time point to differentiate early versus late
recurrence of ICC had not been defined previously. Based
on a large international cohort of patients with ICC, 2 years
was defined empirically as an optimal cutoff to distinguish
early versus late recurrence. In particular, early recurrence
was associated with tumour-specific factors such as large
multiple tumours with microvascular invasion and lymph
nodes metastasis. In contrast, late recurrence was related
more to the underlying non-tumorous liver parenchyma,
in particular the presence of cirrhosis. Although only
genetic and molecular studies of clonal origin can defini-
tively differentiate a recurrence from a second primary,
the present study strongly suggests that early recurrence
of ICC is most likely a recurrence of the initial tumour,
whereas late recurrence is probably a second primary
cancer and potentially related to the background liver.
These findings are important, as the data strongly suggest
that surveillance needs to be focused more intensely on
the first 2 years after resection of ICC, especially among
patients with certain clinical features. The data also pro-
vide prognostic information to help counsel patients and
potentially guide adjuvant treatment planning.
In the present study, the time course of recurrence
after surgical resection of initial tumours was analysed
empirically and the majority of recurrences were noted
to occur within 24 months, with the rate of recurrence
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declining after this time point. Of note, early recurrence
was strongly associated with tumour characteristics includ-
ing lesion size and the presence of satellite lesions. Given
the short time to recurrence, disease that recurs within
24 months may be a consequence of intrahepatic metas-
tasis, microsatellite lesions or even occult residual disease
that was present at the time of the first operation. As
such, special attention should be paid to patients with mul-
tiple large tumours and satellite lesions during the pre-
operative evaluation interval. Although improvement in
accuracy of imaging modalities can help identify tumours
and metastatic lesions, as many as one-third of patients
have occult metastatic or locally advanced disease5,19. Of
note, although not associated with early intrahepatic-only
recurrence, lymph node metastasis was associated with
early any-site recurrence. Moreover, patients who recurred
early were more likely to present with extrahepatic recur-
rence. In turn, patients who experienced an early recur-
rence had a worse long-term outcome than those with a late
recurrence20. Similarly, early recurrence of HCC and col-
orectal liver metastasis after initial hepatectomy have been
associated with worse long-term outcomes16,21,22. As such,
adjuvant therapy following resection of ICC should be con-
sidered to decrease the probability of tumour recurrence
after surgical resection23,24. Further, it has been reported25
that use of chemotherapy is associated with a survival bene-
fit for patients with ICC and nodal metastasis and advanced
tumour stage.
Although tumour factors were associated with early
recurrence, underlying liver cirrhosis was the only factor
associated with late recurrence. Previous studies7–9 noted
that recurrence following resection of ICC with curative
intent was associated with liver cirrhosis, as well as tumour
characteristics. However, none of these studies specifi-
cally examined the timing of recurrence relative to the
pattern of recurrent disease or time of recurrence. The
present study not only identified liver cirrhosis as a cause
of intrahepatic-only recurrence, but also noted that it was
associated specifically with a late timing of recurrence.
In addition, many of the patients who experienced a late
recurrence in the setting of cirrhosis also had hepatitis.
These data strongly imply that the late ‘recurrence’ of
ICC may instead be the development of a second primary
tumour. Cirrhosis, secondary to HBV and HCV infec-
tion, primary biliary disease, alcoholic and non-alcoholic
steatohepatitis, can be associated with an increased risk
of ICC development26–30. Hepatocytes and cholangio-
cytes have the same progenitor cell, and therefore both
HBV and HCV may induce carcinogenesis in the two
cell types by a similar mechanism27,28. It has previously
been proposed31 to classify ICC as ‘conventional’ (without
underlying liver disease) or ‘unconventional’ (developing
in a background of non-biliary chronic liver disease and
cirrhosis). As liver cirrhosis is not so common in patients
with ICC as in those with HCC, other factors may account
for the development of metachronous recurrent disease in
patients with ‘conventional’ ICC. Further studies on the
molecular signatures of late recurrent disease are needed
to help classify recurrent ICC32.
A subset of patients with intrahepatic recurrence under-
went repeated attempts at curative therapy. Among this
subset of patients, surgical resection and ablation were both
employed. It has been noted previously20 that local man-
agement, such as surgery, transarterial chemoemboliza-
tion and radiofrequency ablation, are effective in selected
patients with localized intrahepatic and extrahepatic recur-
rence. Similarly, in the present study, the 5-year OS rate
of patients treated with curative intent for their recur-
rence was 63⋅7 per cent, which was not statistically differ-
ent from that of 77⋅1 per cent among patients who never
experienced a recurrence. Similar good outcomes for treat-
ment of recurrent HCC have been published previously16.
Moreover, retreatment with curative intent of patients who
experienced early recurrence achieved postrecurrence sur-
vival comparable with that of patients who developed late
recurrence, and curative treatments should be considered
for patients with tumour recurrence within even 2 years of
initial first surgery.
Acknowledgements
X.-F. Z. was supported in part by the China Scholarship
Council.
Disclosure: The authors declare no conflict of interest.
References
1 Aljiffry M, Abdulelah A, Walsh M, Peltekian K, Alwayn I,
Molinari M. Evidence-based approach to
cholangiocarcinoma: a systematic review of the current
literature. J Am Coll Surg 2009; 208: 134–147.
2 Khan SA, Toledano MB, Taylor-Robinson SD.
Epidemiology, risk factors, and pathogenesis of
cholangiocarcinoma. HPB (Oxford) 2008; 10: 77–82.
3 Zhou XD, Tang ZY, Fan J, Zhou J, Wu ZQ, Qin LX et al.
Intrahepatic cholangiocarcinoma: report of 272 patients
compared with 5829 patients with hepatocellular carcinoma.
J Cancer Res Clin Oncol 2009; 135: 1073–1080.
4 Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM.
Treatment and prognosis for patients with intrahepatic
cholangiocarcinoma: systematic review and meta-analysis.
JAMA Surg 2014; 149: 565–574.
5 Weber SM, Jarnagin WR, Klimstra D, DeMatteo RP, Fong
Y, Blumgart LH. Intrahepatic cholangiocarcinoma:
© 2017 BJS Society Ltd www.bjs.co.uk BJS 2018; 105: 848–856
Published by John Wiley & Sons Ltd
856 X.-F. Zhang, E. W. Beal, F. Bagante, J. Chakedis, M. Weiss, I. Popescu et al.
resectability, recurrence pattern, and outcomes. J Am Coll
Surg 2001; 193: 384–391.
6 Amini N, Ejaz A, Spolverato G, Kim Y, Herman JM, Pawlik
TM. Temporal trends in liver-directed therapy of patients
with intrahepatic cholangiocarcinoma in the United States: a
population-based analysis. J Surg Oncol 2014; 110: 163–170.
7 Spolverato G, Kim Y, Alexandrescu S, Marques HP,
Lamelas J, Aldrighetti L et al. Management and outcomes of
patients with recurrent intrahepatic cholangiocarcinoma
following previous curative-intent surgical resection. Ann
Surg Oncol 2016; 23: 235–243.
8 Hyder O, Hatzaras I, Sotiropoulos GC, Paul A,
Alexandrescu S, Marques H et al. Recurrence after operative
management of intrahepatic cholangiocarcinoma. Surgery
2013; 153: 811–818.
9 Sulpice L, Rayar M, Boucher E, Pracht M, Meunier B,
Boudjema K. Treatment of recurrent intrahepatic
cholangiocarcinoma. Br J Surg 2012; 99: 1711–1717.
10 Poon RT. Differentiating early and late recurrences after
resection of HCC in cirrhotic patients: implications on
surveillance, prevention, and treatment strategies. Ann Surg
Oncol 2009; 16: 792–794.
11 Poon RT, Fan ST, Lo CM, Liu CL, Ng IO, Wong J.
Long-term prognosis after resection of hepatocellular
carcinoma associated with hepatitis B-related cirrhosis. J
Clin Oncol 2000; 18: 1094–1101.
12 Chen PJ, Chen DS, Lai MY, Chang MH, Huang GT, Yang
PM et al. Clonal origin of recurrent hepatocellular
carcinomas. Gastroenterology 1989; 96: 527–529.
13 Ng IO, Guan XY, Poon RT, Fan ST, Lee JM.
Determination of the molecular relationship between
multiple tumour nodules in hepatocellular carcinoma
differentiates multicentric origin from intrahepatic
metastasis. J Pathol 2003; 199: 345–353.
14 Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J.
Different risk factors and prognosis for early and late
intrahepatic recurrence after resection of hepatocellular
carcinoma. Cancer 2000; 89: 500–507.
15 Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa
K, Miyagawa S et al. Risk factors contributing to early and
late phase intrahepatic recurrence of hepatocellular
carcinoma after hepatectomy. J Hepatol 2003; 38: 200–207.
16 Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti
A, Tiberio GA et al. Early and late recurrence after liver
resection for hepatocellular carcinoma: prognostic and
therapeutic implications. Ann Surg 2006; 243: 229–235.
17 Cucchetti A, Piscaglia F, Caturelli E, Benvegnù L, Vivarelli
M, Ercolani G et al. Comparison of recurrence of
hepatocellular carcinoma after resection in patients with
cirrhosis to its occurrence in a surveilled cirrhotic
population. Ann Surg Oncol 2009; 16: 413–422.
18 Edge SB, Compton CC, Fritz AG, Greene FL, Trotti A.
AJCC Cancer Staging Manual (7th edn). Springer: New York,
2010.
19 Goere D, Wagholikar GD, Pessaux P, Carrere N, Sibert A,
Vilgrain V et al. Utility of staging laparoscopy in subsets of
biliary cancers: laparoscopy is a powerful diagnostic tool in
patients with intrahepatic and gallbladder carcinoma. Surg
Endosc 2006; 20: 721–725.
20 Park HM, Yun SP, Lee EC, Lee SD, Han SS, Kim SH et al.
Outcomes for patients with recurrent intrahepatic
cholangiocarcinoma after surgery. Ann Surg Oncol 2016; 23:
4392–4400.
21 Vigano L, Capussotti L, Lapointe R, Barroso E, Hubert C,
Giuliante F et al. Early recurrence after liver resection for
colorectal metastases: risk factors, prognosis, and treatment.
A LiverMetSurvey-based study of 6025 patients. Ann Surg
Oncol 2014; 21: 1276–1286.
22 Shah SA, Greig PD, Gallinger S, Cattral MS, Dixon E, Kim
RD et al. Factors associated with early recurrence after
resection for hepatocellular carcinoma and outcomes. J Am
Coll Surg 2006; 202: 275–283.
23 Gil E, Joh JW, Park HC, Yu JI, Jung SH, Kim JM.
Predictors and patterns of recurrence after curative liver
resection in intrahepatic cholangiocarcinoma, for
application of postoperative radiotherapy: a retrospective
study. World J Surg Oncol 2015; 13: 227.
24 Dhanasekaran R, Hemming AW, Zendejas I, George T,
Nelson DR, Soldevila-Pico C et al. Treatment outcomes and
prognostic factors of intrahepatic cholangiocarcinoma. Oncol
Rep 2013; 29: 1259–1267.
25 Miura JT, Johnston FM, Tsai S, George B, Thomas J,
Eastwood D et al. Chemotherapy for surgically resected
intrahepatic cholangiocarcinoma. Ann Surg Oncol 2015; 22:
3716–3723.
26 Welzel TM, Graubard BI, El-Serag HB, Shaib YH, Hsing
AW, Davila JA et al. Risk factors for intrahepatic and
extrahepatic cholangiocarcinoma in the United States: a
population-based case–control study. Clin Gastroenterol
Hepatol 2007; 5: 1221–1228.
27 Shaib YH, El-Serag HB, Nooka AK, Thomas M, Brown
TD, Patt YZ et al. Risk factors for intrahepatic and extrahe-
patic cholangiocarcinoma: a hospital-based case–control
study. Am J Gastroenterol 2007; 102: 1016–1021.
28 Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn
KA. Risk factors of intrahepatic cholangiocarcinoma in the
United States: a case–control study. Gastroenterology 2005;
128: 620–626.
29 Zhou Y, Zhao Y, Li B, Huang J, Wu L, Xu D et al. Hepatitis
viruses infection and risk of intrahepatic cholangio-
carcinoma: evidence from a meta-analysis. BMC Cancer
2012; 12: 289.
30 Sorensen HT, Friis S, Olsen JH, Thulstrup AM,
Mellemkjaer L, Linet M et al. Risk of liver and other types
of cancer in patients with cirrhosis: a nationwide cohort
study in Denmark. Hepatology 1998; 28: 921–925.
31 Sempoux C, Jibara G, Ward SC, Fan C, Qin L, Roayaie S
et al. Intrahepatic cholangiocarcinoma: new insights in
pathology. Semin Liver Dis 2011; 31: 49–60.
32 Zou S, Li J, Zhou H, Frech C, Jiang X, Chu JS et al.
Mutational landscape of intrahepatic cholangiocarcinoma.
Nat Commun 2014; 5: 5696.
© 2017 BJS Society Ltd www.bjs.co.uk BJS 2018; 105: 848–856
Published by John Wiley & Sons Ltd
